reports
Press Release: Sanofi and Regeneron’s Dupixent approved as the first t...
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatmentDupixent, which i...
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a ...
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU wh...
Press Release: Sanofi’s Teizeild recommended for EU approval by the CH...
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Recommendation based on the TN-10 study, demonstrating Teizeild’s ability to delay the onset of stage 3 type 1 diabetes (T1D), compared to placebo, in adults and children with stage 2 T1DIf approved, Teizeild would become the first disease-modifying T1D therapy in the EU Paris, November 14, 2025. The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human ...
Communiqué de presse : Teizeild, un médicament Sanofi, a reçu l’approb...
Communiqué de presse : Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2 Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2 La recommandation s’appuie sur l’étude TN-10, qui démontre la capacité du Teizeild à retarder l’apparition du stade 3 du diabète de type 1 (DT1), par rapport au placebo, chez les adultes et les enfants atteints de DT1 de stad...
Sanofi: 1 director
A director at Sanofi bought 207 shares at 7,909p and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Clos...
- Research Department
IBERIAN DAILY 14 NOVEMBER + 3Q’25 RESULTS. PREVIEWS (ANÁLISIS BANCO SA...
NEWS SUMMARY: ACCIONA, ACCIONA ENERGÍA, ACS, AENA, COLONIAL, ELECTRICITY SECTOR, MERLIN, REPSOL, SANTANDER, TALGO. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’25 results to be released over the coming days in Spain. Markets see profit taking European stock markets ended up with profit taking in a session that ended worse than it began in a technical movement to digest th...
- Research Department
INFORME DIARIO 14 NOVIEMBRE + RDOS. ESPAÑA 3T’25. PREVIEWS (ANÁLISIS B...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACCIONA, ACCIONA ENERGÍA, ACS, AENA, COLONIAL, MERLIN, REPSOL, SANTANDER, SECTOR ELÉCTRICO, TALGO. EUROPA: ALLIANZ, PROSUS. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. Toma de beneficios en mercado Las bolsas terminaron recogiendo beneficio...
Sanofi: Information concerning the total number of voting rights and s...
Sanofi: Information concerning the total number of voting rights and shares – October 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry u...
Sanofi: Informations relatives au nombre de droits de vote et d'action...
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Octobre 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 454 937 946 eurosSiège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris acti...
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi...
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique... ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique ; la demande supplémentaire de licence de mise sur le marché (sBLA) a été acceptée pour examen prioritaire par la FDA Les données de phase 3 qui v...
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study m...
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion, and nasal polyps in patients a...
- Research Department
IBERIAN DAILY 06 NOVEMBER + 3Q'25 RESULTS. HIGHLIGHTS AND REST OF PREV...
NEWS SUMMARY: AENA, ARCELORMITTAL, FCC, LOGISTA, ROVI. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’25 results to be released over the coming days in Spain. Stock markets recover It was another session that ended better than it began for European markets that, after the opening bell in the US and the solid macro data releases, shifted towards green numbers. In the STOXX 6...
- Research Department
INFORME DIARIO 06 NOVIEMBRE + RDOS. ESPAÑA Y EUROPA 3T’25. IDEAS DESTA...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: AENA, ARCELORMITTAL, FCC, LOGISTA, ROVI. EUROPA: DHL. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. Recuperación de los mercados Nueva jornada de menos a más en los mercados europeos, que tras la apertura de las bolsas en EE.UU. y los buenos ...
- Rafael Bonardell
AENA: 3Q’25 RESULTS (ANÁLISIS BANCO SABADELL)
3Q'25 vs. 3Q'24 Results Sales: € 1.789 Bn (+8.4% vs. +8.5% BS(e) and +7.3% consensus); EBITDA: € 1.19 Bn (+7.4% vs. +5.9% BS(e) and +5.9% consensus); 9M'25 vs. 9M'24 Results Sales: € 4.785 Bn (+8.8% vs. +8.9% BS(e) and +8.4% consensus); EBITDA: € 2.883 Bn (+8.2% vs. +7.6% BS(e) and +7.6% consensus);
- Rafael Bonardell
AENA: RDOS. 3T’25 (ANÁLISIS BANCO SABADELL)
Rdos. 3T'25 vs 3T'24: Ventas: 1.789 M euros (+8,4% vs +8,5% BS(e) y +7,3% consenso); EBITDA: 1.190 M euros (+7,4% vs +5,9% BS(e) y +5,9% consenso). Rdos. 9meses'25 vs 9meses'24: Ventas: 4.785 M euros (+8,8% vs +8,9% BS(e) y +8,4% consenso); EBITDA: 2.883 M euros (+8,2% vs +7,6% BS(e) y +7,6% consenso).
Press release: Sanofi successfully prices USD 3 billion of bond issue
Press release: Sanofi successfully prices USD 3 billion of bond issue Sanofi successfully prices USD 3 billion of bond issue Paris, France – October 28, 2025 - Sanofi announces that it has successfully priced its offering of $3 billion of notes across 5 tranches: $400 million fixed rate notes, due November 2027, bearing interest at a rate of 3.75%. $500 million floating rate notes, due November 2027, bearing interest at compounded SOFR plus 0.46%. $400 million fixed rate notes, due November 2028, bearing interest at a rate of 3.80%. $500 million floating rate notes, due November 202...
Communiqué de presse : Sanofi place 3 milliards de dollars d’emprunts ...
Communiqué de presse : Sanofi place 3 milliards de dollars d’emprunts obligataires Sanofi place 3 milliards de dollars d’emprunts obligataires Paris, 28 Octobre 2025 - Sanofi annonce avoir placé avec succès une émission obligataire en 5 tranches (les « obligations ») pour un montant de 3 milliards de dollars : 400 millions de dollars US d’obligations à taux fixe, échéance novembre 2027 portant intérêt au taux de 3.75% 500 millions de dollars US d’obligations à taux variable, échéance novembre 2027, portant intérêt au taux de SOFR capitalisé + 0.46%400 millions de dollars US d’obligat...
- Martial Descoutures
- Emira Sagaama
- Maissa Keskes
- Stephane Houri
AC ACCOR SA
DG VINCI SA
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
RNO RENAULT SA
MTX MTU AERO ENGINES AG
ORA ORANGE SA
SK SEB SA
SW SODEXO SA
ALV ALLIANZ SE
NOKIA NOKIA OYJ
BEI BEIERSDORF AG
ENI ENI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
SAN SANOFI
SAF SAFRAN S.A.
01913 PRADA S.P.A.
BKT BANKINTER SA
ASSA B ASSA ABLOY AB CLASS B
TEC TECHNIPFMC PLC
DHER DELIVERY HERO SE
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
SIK SIKA AG
HAG HENSOLDT AG
DSY DASSAULT SYSTEMES SA
ATCO A ATLAS COPCO AB
SGSN SGS SA
- Emira Sagaama
- Maissa Keskes
- Stephane Houri
AC ACCOR SA
DG VINCI SA
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
RNO RENAULT SA
MTX MTU AERO ENGINES AG
ORA ORANGE SA
SK SEB SA
SW SODEXO SA
ALV ALLIANZ SE
NOKIA NOKIA OYJ
BEI BEIERSDORF AG
ENI ENI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
SAN SANOFI
SAF SAFRAN S.A.
01913 PRADA S.P.A.
BKT BANKINTER SA
ASSA B ASSA ABLOY AB CLASS B
TEC TECHNIPFMC PLC
DHER DELIVERY HERO SE
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
SIK SIKA AG
HAG HENSOLDT AG
DSY DASSAULT SYSTEMES SA
ATCO A ATLAS COPCO AB
SGSN SGS SA
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.